# Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study

> **NCT00553358** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 455 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** Lapatinib
- **BIOLOGICAL:** Trastuzumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00553358
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01-05
- **Primary completion:** 2010-05-27
- **Final completion:** 2019-12-23
- **Target enrollment:** 455 (ACTUAL)
- **Last updated:** 2021-09-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00553358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00553358, "Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00553358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*